MRNA Stock Analysis: Buy, Sell, or Hold?
MRNA - Moderna, Inc. Common Stock
$47.72
-1.84 (-3.71%)
▼
5d:
-6.94%
30d:
-10.92%
90d:
+52.95%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
MRNA is down 4.8% this week, but smart money is accumulating calls. Top strike: $50 2026-05-15 with 25,043 OI. Call ratio: 70% View Scanner →
Strength: 4.5/10
Get Alerted When MRNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MRNA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MRNA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MRNA is currently trading at $47.72, which is considered oversold relative to its 30-day fair value range of $50.30 to $54.54.
Technical Outlook: Technically, MRNA is in a strong uptrend. The price is currently testing key support at $48.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $43.75. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MRNA is in a strong uptrend. The price is currently testing key support at $48.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $43.75. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$50.30 -
$54.54
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.8%
Protect Your Profits
Holding MRNA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BEARISH: Trading 11.7% above Wall St target ($43.75)
- CAUTION: Recommendation downgraded due to -6.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$50.30 -
$54.54
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$48.10
Resistance Level
$56.51
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.90
Wall Street Target
$43.75
(-11.7%)
Revenue Growth (YoY)
-29.8%
Earnings Growth (YoY)
-85.1%
Profit Margin
-145.2%
Share & Embed Analysis
Last updated: March 30, 2026 1:32 PM ET
Data refreshes hourly during market hours. Next update: 2:32 PM
Data refreshes hourly during market hours. Next update: 2:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRNA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Stephen Hoge
SELL
160009 shares
2026-02-23
Ro Khanna
BUY
2026-01-23
Noubar Afeyan
SELL
23853 shares
2025-12-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 53 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 51 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
Advanced MRNA Option Strategies
Professional options setups generated by AI based on today's MRNA price and gamma walls.
